Abstract
We discuss two of the most common of the acquired inflammatory neuropathies: Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy, as well as their variants. We review their clinical presentation, electrophysiologic findings, and management, highlighting knowledge gained from the recent literature. Unfortunately, although treatments exist for both Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy, none are completely curative and all have significant potential side effects and/ or expense. Better understanding of the underlying pathophysiology of these diseases is needed in order to develop more targeted therapies.
Similar content being viewed by others
References and Recommended Reading
Jacobs BC, Rothbarth PH, van der Meche N, et al.: The spectrum of antecedent infections in Guillain Barre syndrome. A casecontrol study. Neurology 1998, 51:1110–1115.
Ogawara K, Kuwabara S, Mori, et al.: Axonal Guillain-Barre syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 2000, 48:624–631.
Brannagan TH 3rd, Zhou Y: HIV-associated Guillain-Barre syndrome. J Neurol Sci 2003, 208(1-2):39–42.
Wen PY, Alyea EP, Simon D, et al.: Guillain-Barre syndrome following allogeneic bone marrow transplantation. Neurology 1997, 49:1711–1714.
Lasky T, Terracciano GJ, Magder L, et al.: The Guillain-Barre syndrome and the 1992–1993 and 1993–1994 influenza vaccines. N Engl J Med 1998, 339:1797–1802.
Pritchard J, Mukherjee R, Hughes RA: Risk of relapse of Guillain-Barre syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunization. J Neurol Neurosurg Psychiatry 2002, 73:348–349.
Wijdicks EF, Fletcher DD, Lawn ND: Influenza vaccine and the risk of relapse of Guillain-Barre syndrome. Neurology 2000, 55:452–453.
Oh SJ, Kurokawa K, de Almeida DF, Ryan HF Jr, Claussen GC: Subacute inflammatory demyelinating polyneuropathy. Neurology 2003, 61:1507–1512.
Rees JH, Thompson RD, Smeeton NC, Hughes RA: Epidemiological study of Guillain-Barre syndrome in south east England. J Neurol Neurosurg Psychiatry 1998, 64:74–77.
Fletcher DD, Lawn ND, Wolter TD, Wijdicks EF: Long-term outcome in patients with Guillain-Barre syndrome requiring mechanical ventilation. Neurology 2000, 54:2311–2315.
Hiraga A, Mori M, Ogawara K, et al.: Differences in patterns of progression in demyelinating and axonal Guillain-Barre syndromes. Neurology 2003, 61:471–474.
Kuwabara S, Asahina M, Mori M, et al.: Two patterns of clinical recovery in Guillain-Barre syndrome with anti-GM1 antibody. Neurology 1998, 51:1656–1660.
Yuki N, Taki T, Inagaki F, et al.: A bacterium lipopolysaccaride that elicits Guillain-Barre syndrome has a GM1 gangliosidelike structure. J Exp Med 1993, 178:1771–1775.
Hafer-Macko CE, Sheikh KA, Li CY, et al.: Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996, 39:625–635.
Hafer-Macko CE, Hsieh ST, Li CY, et al.: Acute motor axonal neuropathy: an antibody mediated attack on axolemma. Ann Neurol 1996, 40:635–644.
Hughes RA, Wijdicks EF, Barohn R, et al.: Practice parameter: immunotherapy for Guillain-Barre syndrome. Report of the Quality of Standard Subcommittee of the American Academy of Neurology. Neurology 2003, 61:736–740. This is an excellent review of the published clinical trials of treatment in GBS with evidence-based recommendations for management of GBS patients.
Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group: Randomised trial of plasma exchange, intravenous immunoglobulin and combined treatments in Guillain-Barre syndrome. Lancet 1997, 349:225–230.
van Koningsveld R, Schmitz PI, van der Meche FG, et al.: Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomized trial. Lancet 2004, 363:192–196.
Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force: Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Adacemy of Neurology AIDS Task Force. Neurology 1991, 41:617–618.
Barohn RJ, Kissel JT, Warmolts JR, Mendell JR: Chronic inflammatory demyelinating polyradiculoneuropathy: clinical characteristics, course and recommendations for diagnostic criteria. Arch Neurol 1989, 46:878–884.
Schimdt B, Toyka KV, Kiefer R, et al.: Inflammatory infiltrates in sural nerve biopsies in Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 1996, 19:474–487.
Kieseier BC, Dalakas MC, Hartung HP: Immune mechanisms in chronic inflammatory demyelinating neuropathy. Neurology 2002, 59(Suppl 6):S7-S12.
Dyck PJ, O’Brien PC, Oviatt KF, et al.: Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982, 11:136–141.
Dyck PJ, Daube J, O’Brien P, et al.: Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986, 314:461–465.
Hahn AF, Bolton CF, Pillay N, et al.: Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: a double-blind, sham-controlled, cross-over study. Brain 1996, 119:1055–1066.
Hahn AF, Bolton CF, Zochodne D, Feasby TE: Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebocontrolled, cross-over study. Brain 1996, 119:1067–1077.
Dyck PJ, Litchy WJ, Kratz KM, et al.: A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994, 36:838–845.
Mendell JR, Barohn RJ, Freimer ML, et al.: Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001, 56:445–449. This is a randomized controlled trial that demonstrated the efficacy of IVIg as first-line treatment in CIDP.
Hughes R, Bensa S, Wilson H, et al.: Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001, 50:195–201.
Radziwill AJ, Steck AJ, Renaud S, Fuhr P: Distal motor latency and residual latency as sensitive markers of anti-MAG polyneuropathy. J Neurol 2003, 250:962–966.
Katz JS, Saperstein DS, Gronseth G, et al.: Distal acquired demyelinating symmetric neuropathy. Neurology 2000, 54:615–620. This is a retrospective review article that characterizes a distal variant of CIDP and describes its response to treatment.
Saperstein DS, Katz JS, Amato AA, Barohn RJ: Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001, 24:311–324.
Gorson KC, Ropper AH, Weinberg DH, Weinstein R: Treatment experience in patients with anti-myelin-associated glycoprotein neuropathy. Muscle Nerve 2001, 24:778–786.
Dalakas MC, Quarles RH, Farrer RG, et al.: A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 1996, 40:792–795.
Dyck PJ, Low PA, Windebank AJ, et al.: Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 1991, 325:1482–1486.
Nobile-Orazio E, Meucci M, Baldini L, et al.: Long-term prognosis of neuropathy associated with anti-MAG IgM Mproteins and its relationship to immune therapies. Brain 2000, 123:710–717.
Saperstein DS, Amato AA, Wolfe GI, et al.: Multifocal acquired demyelinating sensory and motor neuropathy. The Lewis-Sumner syndrome. Muscle Nerve 1999, 22:560–566.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Briemberg, H.R., Amato, A.A. Inflammatory neuropathies. Curr Neurol Neurosci Rep 5, 66–71 (2005). https://doi.org/10.1007/s11910-005-0026-z
Issue Date:
DOI: https://doi.org/10.1007/s11910-005-0026-z